|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM307977935 |
| 003 |
DE-627 |
| 005 |
20231225130740.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2020 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.3928/23258160-20200228-03
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1026.xml
|
| 035 |
|
|
|a (DE-627)NLM307977935
|
| 035 |
|
|
|a (NLM)32211904
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Ebrahimiadib, Nazanin
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab
|
| 264 |
|
1 |
|c 2020
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 14.04.2021
|
| 500 |
|
|
|a Date Revised 14.04.2021
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright 2020, SLACK Incorporated.
|
| 520 |
|
|
|a BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB)
|
| 520 |
|
|
|a PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared
|
| 520 |
|
|
|a RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 logMAR (P = .001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 μm to 364 μm (P = .004) after the first IVZ injections and remained significant
|
| 520 |
|
|
|a CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:145-151.]
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Angiogenesis Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Recombinant Fusion Proteins
|2 NLM
|
| 650 |
|
7 |
|a aflibercept
|2 NLM
|
| 650 |
|
7 |
|a 15C2VL427D
|2 NLM
|
| 650 |
|
7 |
|a Bevacizumab
|2 NLM
|
| 650 |
|
7 |
|a 2S9ZZM9Q9V
|2 NLM
|
| 650 |
|
7 |
|a Receptors, Vascular Endothelial Growth Factor
|2 NLM
|
| 650 |
|
7 |
|a EC 2.7.10.1
|2 NLM
|
| 700 |
1 |
|
|a Lashay, Alireza
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Riazi-Esfahani, Hamid
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jamali, Sepideh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Khodabandeh, Alireza
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zarei, Mohammad
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Roohipoor, Ramak
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Khojasteh, Hassan
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Bazvand, Fatemeh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ojani, Mina
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shahabinejad, Mojtaba
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yaseri, Mehdi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Modjtahedi, Bobeck S
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Davoudi, Samaneh
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Riazi-Esfahani, Mohammad
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Ophthalmic surgery, lasers & imaging retina
|d 2013
|g 51(2020), 3 vom: 01. März, Seite 145-151
|w (DE-627)NLM224956647
|x 2325-8179
|7 nnns
|
| 773 |
1 |
8 |
|g volume:51
|g year:2020
|g number:3
|g day:01
|g month:03
|g pages:145-151
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.3928/23258160-20200228-03
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_31
|
| 912 |
|
|
|a GBV_ILN_40
|
| 912 |
|
|
|a GBV_ILN_63
|
| 912 |
|
|
|a GBV_ILN_65
|
| 912 |
|
|
|a GBV_ILN_69
|
| 912 |
|
|
|a GBV_ILN_70
|
| 912 |
|
|
|a GBV_ILN_90
|
| 912 |
|
|
|a GBV_ILN_91
|
| 912 |
|
|
|a GBV_ILN_130
|
| 912 |
|
|
|a GBV_ILN_135
|
| 912 |
|
|
|a GBV_ILN_136
|
| 912 |
|
|
|a GBV_ILN_151
|
| 912 |
|
|
|a GBV_ILN_181
|
| 912 |
|
|
|a GBV_ILN_203
|
| 912 |
|
|
|a GBV_ILN_217
|
| 912 |
|
|
|a GBV_ILN_235
|
| 912 |
|
|
|a GBV_ILN_289
|
| 912 |
|
|
|a GBV_ILN_294
|
| 912 |
|
|
|a GBV_ILN_297
|
| 912 |
|
|
|a GBV_ILN_350
|
| 912 |
|
|
|a GBV_ILN_352
|
| 912 |
|
|
|a GBV_ILN_674
|
| 912 |
|
|
|a GBV_ILN_676
|
| 912 |
|
|
|a GBV_ILN_688
|
| 912 |
|
|
|a GBV_ILN_698
|
| 912 |
|
|
|a GBV_ILN_721
|
| 912 |
|
|
|a GBV_ILN_737
|
| 912 |
|
|
|a GBV_ILN_791
|
| 912 |
|
|
|a GBV_ILN_812
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 51
|j 2020
|e 3
|b 01
|c 03
|h 145-151
|